Continuous vs. intermittent beta-lactam dosing in critically ill patients with sepsis: A randomized controlled trial.
Not Applicable
- Conditions
- Sepsis
- Registration Number
- PACTR202009811610400
- Lead Sponsor
- Applied for and awaiting approval
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 408
Inclusion Criteria
All patients, adult and paediatric, admitted to the intensive care unit with sepsis
Prescription of one of four beta lactam antibiotics by treating doctor:
1.Amoxicillin- clavulanate
2.Piperacillin-tazobactam
3.Meropenem
4.Imipenem
Anticipated ICU at least 48 hours.
Exclusion Criteria
Pregnancy
Less than 1 month old
Chronic renal failure (eGFR<30ml/min)
Patient admitted and already on renal replacement therapy
Inadequate intravenous access
Infections in which standard recommended antibiotic duration is > 14 days (eg: infective endocarditis, osteomyelitis)
Patients receiving palliative care at study assessment
Patient previously enrolled on this study
Declined consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method